Eli Lilly and Company (NYSE: LLY) and Sarah Cannon Research Institute (SCRI) today announced a strategic partnership to co‑develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor. Under the agreement, SCRI will collaborate with Lilly to provide clinical development expertise and program design, as well as medical oversight and trial management. Patient enrollment for the initial Phase II clinical trial is underway.
"Lilly has a long history of leading innovation in cancer therapy with the goal to offer patients improved treatment outcomes," said Christopher A. Slapak, M.D., vice president, early phase clinical research for Lilly. "This strategic partnership is an exciting step to foster further collaboration with SCRI in advancing the field of cancer research."
The partnership supports the development of this novel targeted cancer therapy, including flexible and efficient program design and implementation, as well as more rapid patient enrollment to clinical trials by accessing SCRI's large network of patients.
"Our clinical trial management capabilities and scientific leadership, combined with Lilly's leading drug development expertise, furthers our mission to advance therapies for patients seeking novel cancer medicines," said Dee Anna Smith, CEO of SCRI. "Through partnerships like this one, we can accelerate the time it takes to bring clinical trials into communities for those fighting cancer."
Rising antibiotic resistance prompts shift to ecological research strategies in infection control